Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + sintilimab + oxaliplatin + 5-fluorouracil + leucovorin
- Development stage
- Phase 2
- Lead developer
- Sun Yat-sen University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy regimen consists of the multi-kinase inhibitor lenvatinib, the PD-1 inhibitor sintilimab, and the FOLFOX chemotherapy backbone (oxaliplatin, 5-fluorouracil, and leucovorin). It is primarily being investigated as a first-line treatment for patients with metastatic intrahepatic cholangiocarcinoma (ICC). Lenvatinib targets multiple receptor tyrosine kinases involved in angiogenesis and tumor progression, including VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET. Sintilimab is a monoclonal antibody that enhances the anti-tumor immune response by blocking the programmed cell death protein 1 (PD-1) receptor. The FOLFOX component provides cytotoxic activity through oxaliplatin-induced DNA damage and 5-fluorouracil-mediated inhibition of thymidylate synthase, with leucovorin acting as a biochemical modulator to enhance the efficacy of 5-fluorouracil.
- Other names
- Lenvatinib + Sintilimab + FOLFOXLenvatinib + Sintilimab + Oxaliplatin + 5-fluorouracil + Leucovorin
02
Targets
DNAFGFR1 (Fibroblast growth factor receptor 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on lenvatinib + sintilimab + oxaliplatin + 5-fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + sintilimab + oxaliplatin + 5-fluorouracil + leucovorin.